Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Participant characteristics and plasma biomarker levels across ckd stages

From: The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity

 

CKD Stage-1 (N = 147)

CKD Stage-2 (N = 88)

CKD Stage-3 (N = 6)

Age, median (Q1-Q3)

67.1 (62.5–72.1)

73.0 (69.0–77.3)

78.2 (74.9–79.2)

Female, n(%)

97 (66.0%)

61 (69.3%)

2 (33.3%)

YOE, median (Q1-Q3)

15.0 (12.0–17.0)

15.0 (12.0–18.0)

18.0 (17.3–19.5)

MMSE, Median (Q1-Q3)

29.0 (27.3–30.0) [21]

28.5 (26.0–30.0) [8]

29.0 (28.3–29.8) [0]

APOE ε4 carriers, No. (%)

50 (34.0%) [3]

26 (29.5%) [0]

2 (33.3%) [0]

Amyloid status, No. (%)

61 (41.5%)

37 (42.0%)

2 (33.3%)

Plasma p-tau217, median (Q1-Q3), pg/mL

0.305 (0.188–0.693) [10]

0.418 (0.263–0.812) [13]

0.572 (0.550–0.890) [0]

Plasma p-tau181, median (Q1-Q3), pg/mL

7.98 (5.62–11.9) [1]

8.46 (6.73–12.5) [1]

11.6 (10.5–15.5) [0]

Plasma p-tau231, median (Q1-Q3), pg/mL

14.1 (10.6–20.2) [2]

16.5 (12.5–20.6) [1]

23.8 (19.7–31.5) [0]

Plasma NTA-tau, median (Q1-Q3), pg/mL

0.213 (0.118–0.410) [4]

0.251 (0.123–0.399) [3]

0.282 (0.220–0.447) [0]

Plasma GFAP, median (Q1-Q3), pg/mL

149 (104–218) [0]

181 (143–252) [1]

236 (190–257) [0]

Plasma NfL, median (Q1-Q3), pg/mL

18.8 (14.4–27.1) [0]

26.8 (18.5–32.7) [1]

40.4 (31.7–48.7) [0]

Plasma Aβ42, median (Q1-Q3), pg/mL

6.17 (4.86–7.15) [0]

6.84 (5.79–7.77) [1]

8.50 (6.76–10.3) [0]

Plasma Aβ40, median (Q1-Q3), pg/mL

89.6 (77.2–100) [0]

93.8 (84.8–105) [1]

124 (113–143) [0]

Plasma Aβ42/40, median (Q1-Q3), pg/mL

0.0682 (0.0608–0.0789) [0]

0.0732 (0.0611–0.0828) [1]

0.0679 (0.0636–0.0811) [0]

  1. Categorical variables are reported as counts and percentages, while continuous variables are presented as median values with interquartile ranges (Q1-Q3). Missing values are reported in brackets next to the respective variables
  2. Abbreviations: CKD Chronic kidney disease, YOE Years of Education, MMSE Mini-Mental State Examination, APOE Apolipoprotein E, eGFR Estimated Glomerular Filtration Rate, p-tau phosphorylated tau, NTA-tau N-terminal containing tau fragments, GFAP Glial Fibrillary Acidic Protein, NfL Neurofilament Light chain, Aβ Amyloid Beta
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193